$\require{mediawiki-texvc}$
  • 검색어에 아래의 연산자를 사용하시면 더 정확한 검색결과를 얻을 수 있습니다.
  • 검색연산자
검색연산자 기능 검색시 예
() 우선순위가 가장 높은 연산자 예1) (나노 (기계 | machine))
공백 두 개의 검색어(식)을 모두 포함하고 있는 문서 검색 예1) (나노 기계)
예2) 나노 장영실
| 두 개의 검색어(식) 중 하나 이상 포함하고 있는 문서 검색 예1) (줄기세포 | 면역)
예2) 줄기세포 | 장영실
! NOT 이후에 있는 검색어가 포함된 문서는 제외 예1) (황금 !백금)
예2) !image
* 검색어의 *란에 0개 이상의 임의의 문자가 포함된 문서 검색 예) semi*
"" 따옴표 내의 구문과 완전히 일치하는 문서만 검색 예) "Transform and Quantization"
쳇봇 이모티콘
안녕하세요!
ScienceON 챗봇입니다.
궁금한 것은 저에게 물어봐주세요.

논문 상세정보

Abstract

A kinetic assay was carried out in order to compare the ability of detection for prekallikrein activator(PKA) in plasma-derived products with that of an endpoint assay and a commercial method. Using these methods, 9 human albumin preparations were assayed and compared to each other. The coefficient of variation between the Kinetic assay and the end point assay was found within 6.6% and this result showed that two methods were highly correlative and the end point assay could act as a replacement of the kinetic assay. Another important goal of this study was to investigate the reproducibility among laboratories on the kinetic assay. A collaborative study was performed to validate the kinetic method with intra and inter assays. The coefficient of variation for the intra assay of each laboratory was less than 4% and that for between individuals in the inter assay was 4.1%. These results revealed that the kinetic assay showed good reproducibility. The contents of PKA in plasma-derived products were also determined by the kinetic assay. As a result, it was found that trace amounts of PKA were present in 32 human immunoglobulin preparations, however the average concentration of PKA in 171 albumin preparations was 5.8 IU/mL.

참고문헌 (16)

  1. Alving, B. M., Tankersley, D. L., Mason, B. L., Rossi, F., Aronson, D. L. and Finlayson, J. S., Contact-activated Factors: Contaminants of immunoglobulin preparations with coagulant and vasoactive properties. J. Lab. Clin. Med., 96, 334-346 (1980) 
  2. Clements, J., Mukhtar, A., Yan, S. and Holland, A., Kallikreins and kinins in inflammatory-like events in the reproductive tract. Pharm. Res., 35(6), 537-540 (1997) 
  3. Fossum, S., Hoem, N., Gjonnass, H. and Briseid, K., Contact activation factors in plasma from women on estrogen replacement therapy after ovariohysterectomy. Thromb. Res., 93, 16170(1999) 
  4. Griffin, J.H., Role of surface in surface-dependent activation of Hageman factor (blood coagulation factor XII). Proc. Natl. Acad. Sci,. 75(4), 1998-2002(1978) 
  5. Heinonen, J., Peltola, K., Himberg, J.J. and Suomela, H., Hypotensive Effect of Prekallkirein activator (PKA) in plasma protein fraction (PPF). Dev. Biol. Stand., 48, 129-130(1980) 
  6. Heinonen, J., Peltola, K., Himberg, J. J. and Suomela, H., Correlation of hypotensive effect of plasma protein fraction with prekallikrein activator activity: a clinical study in patients having open-heart surgery. Ann. Thorac. Surg., 33(3), 244-249 (1982) 
  7. Kaplan, A. P., Joseph, K. and Silverberg, M., Pathways for bradykinin formation and inflammatory disease. J. Allerg. Clin. Immunol., 109(2), 195-209(2002) 
  8. Kaplan, A. P., Initiation of the intrinsic coagulation and fibrinolytic pathways of man: The role of surfaces, Hageman factor, prekallikrein, high molecular weight kininogen, and factor XI. Prog. Hemost. Thromb., 4, 127-175(1978) 
  9. Regoli, D., Rizzi, A. and Calo, G., Pharmacology of the kallikrein-kinin system. Pharma. Res., 35(6), 513-515(1997) 
  10. Revak, S. D., Cochrane, C. G., Johnston, A. R. and Hugli, T. E., Structural changes accompanying enzymatic activation of human Hageman factor. J. Clin. Invest., 54(3), 619-627(1974) 
  11. Rob E., Van Rosevelt, R. E., Bakker, J. C., Sinclair, D. M., Damen, J. and Van Mourik, J. A., Bradykinin-mediated hypotension after infusion of plasma-protein fraction. J. Lab. Clin. Med., 100, 288-295(1982) 
  12. Shin, I. S., Shim, Y. B., Hong, C. M., Koh, H. C., Lee, S. H. and Hong, S. H., An improved, reliable and practical kinetic assay for the detection of prekallikrein activator in blood products. Arch. Pharm. Res., 25(4), 505-510(2002) 
  13. Snape, T. J., Griffith, D., Vallet, L. and Wesley, E. D., The assay of prekallikrein activator in human blood products. Dev. Biol. Stand., 44, 115-120(1979) 
  14. Tankersley, D. L., Fournel, M. A. and Schroeder, D. D., Kinetics of activation of prekallikrein by prekallikrein activator. Biochemistry, 19(14), 3121-3127(1980) 
  15. Turner, P. J., Young, I. F., Marley, P. B., Herrington, R. W. and Schiff, P., Albumin solutions: Their production and quality control. Dev. Biol.. Stand., 67, 119-127(1987) 
  16. Yasda, J., Ueno, G, Kuratsuka, K., Homma, R., Hara, S., Kazama, M. and Ito, H., Japanese minimum requirements for albumin preparations recent amendments and current problems. Dev. Biol. Stand., 48, 143-52(1981) 

이 논문을 인용한 문헌 (0)

  1. 이 논문을 인용한 문헌 없음

원문보기

원문 PDF 다운로드

  • ScienceON :

원문 URL 링크

원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다. (원문복사서비스 안내 바로 가기)

상세조회 0건 원문조회 0건

DOI 인용 스타일